Allergan: Waiting for a Deal
July 22, 2014 at 14:11 PM EDT
UBS analyst Marc Goodman explains why he raised Allergan (AGN) to Buy from Neutral following yesterday’s financial results and cost-cutting moves: Reuters Allergan Chief Executive David Pyott Investors have been waiting for 2 Allergan events: a restructuring and an accretive deal. Given the Friday PR for the conf call [yesterday], many investors were expecting a [...]
